RxDoctor Payments Data

Mark Avila, MD

Gastroenterology · Miami, FLNPI 1598742058

Payments from drug & device makers

$167,107in general payments, 2019–2025

Across 502 payments — averaging $332.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$80K
  • F. Hoffmann-la Roche AG$78K
  • Intercept Pharmaceuticals, Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$928
  • AbbVie$891
  • plus $5K from 34 others

What the payments were for

  • Speaking & faculty fees$430%
  • Food & beverage$9,23396%
  • Education$3223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,107 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$52,863
Medicare patients
121
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid11$101,949
XifaxanRifaximin27$87,588
VemlidyTenofovir Alafenamide19$30,780
ClenpiqSod Picosulf/Mag Ox/Citric Ac102$17,346
LinzessLinaclotide15$7,929
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates101$6,792
Ursodiol25$2,133
Omeprazole141$1,927
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag12$1,473
SuprepSodium, Potassium,mag Sulfates13$1,206
Pantoprazole Sodium174$1,012
Famotidine96$974
Esomeprazole Magnesium40$676
Dicyclomine Hcl42$580
Sucralfate19$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$1,542$101,94911 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,382$87,58827 claims
GileadVemlidy$928$30,78019 claims
Ferring Pharmaceuticals Inc.Clenpiq$49$17,346102 claims
AbbVieLinzess$891$7,92915 claims
Braintree Laboratories, Inc.Suflave$74$1,47312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →